| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2015PLoSO..1036121Z |
| P356 | DOI | 10.1371/JOURNAL.PONE.0136121 |
| P932 | PMC publication ID | 4537303 |
| P698 | PubMed publication ID | 26275173 |
| P5875 | ResearchGate publication ID | 281119540 |
| P50 | author | S M Jones | Q69374397 |
| P2093 | author name string | Jeong-Woo Seo | |
| Lawrence D Snell | |||
| J Paul Elliott | |||
| Emil Zeynalov | |||
| P2860 | cites work | Physiologic concentrations of arginine vasopressin activate human platelets in vitro | Q71045277 |
| Effects of SR 49059, a new orally active and specific vasopressin V1 receptor antagonist, on vasopressin-induced vasoconstriction in humans | Q73879461 | ||
| Conivaptan (Vaprisol) for hyponatremia | Q79755713 | ||
| Conivaptan: YM 087 | Q80417027 | ||
| Treatment of the syndrome of inappropriate secretion of antidiuretic hormone with urea in critically ill patients | Q83540878 | ||
| Collecting duct-specific knockout of endothelin-1 alters vasopressin regulation of urine osmolality | Q28508192 | ||
| Heart disease and stroke statistics--2014 update: a report from the American Heart Association | Q29547691 | ||
| Effect of osmotherapy with hypertonic saline on regional cerebral edema following experimental stroke: a study utilizing magnetic resonance imaging | Q31119950 | ||
| Evaluation of the secretory pattern of plasma arginine vasopressin in stroke patients. | Q32063277 | ||
| Water entry into astrocytes during brain edema formation | Q33324470 | ||
| Arginine-vasopressin V1 but not V2 receptor antagonism modulates infarct volume, brain water content, and aquaporin-4 expression following experimental stroke | Q33508851 | ||
| A spoonful of sugar helps the medicine go down: a novel technique to improve oral gavage in mice | Q33880128 | ||
| The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists | Q34192690 | ||
| Treatment of stroke related refractory brain edema using mixed vasopressin antagonism: a case report and review of the literature | Q34544328 | ||
| Selective vasopressin-1a receptor antagonist prevents brain edema, reduces astrocytic cell swelling and GFAP, V1aR and AQP4 expression after focal traumatic brain injury | Q34554602 | ||
| Arginine-vasopressin V1a receptor inhibition improves neurologic outcomes following an intracerebral hemorrhagic brain injury | Q34713880 | ||
| The syndrome of inappropriate antidiuretic hormone secretion | Q35161602 | ||
| Neurological impact of vasopressin dysregulation and hyponatremia | Q36377918 | ||
| Post-treatment with SR49059 improves outcomes following an intracerebral hemorrhagic stroke in mice | Q36585575 | ||
| Vaptans and hyponatremia in critical patients | Q37058365 | ||
| Mechanisms, risks, and new treatment options for hyponatremia | Q37147030 | ||
| The perivascular pool of aquaporin-4 mediates the effect of osmotherapy in postischemic cerebral edema | Q37371489 | ||
| Hyponatremia and antidiuresis syndrome | Q37961312 | ||
| Brain edema formation correlates with perfusion deficit during the first six hours after experimental subarachnoid hemorrhage in rats. | Q42146490 | ||
| Open-label randomized trial of the safety and efficacy of a single dose conivaptan to raise serum sodium in patients with traumatic brain injury | Q42694389 | ||
| Vasopressin receptor antagonists: the vaptans | Q42786149 | ||
| Effect of small molecule vasopressin V1a and V2 receptor antagonists on brain edema formation and secondary brain damage following traumatic brain injury in mice. | Q43139485 | ||
| Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience. | Q43197396 | ||
| Arginine vasopressin stimulation of cerebral microvascular endothelial cell Na-K-Cl cotransporter activity is V1 receptor and [Ca] dependent | Q44173254 | ||
| Protective effect of the V1a receptor antagonist SR49059 on brain edema formation following middle cerebral artery occlusion in the rat. | Q44919821 | ||
| Modulation of AQP4 expression by the selective V1a receptor antagonist, SR49059, decreases trauma-induced brain edema. | Q44947019 | ||
| The role of vasopressin V1A receptors in cytotoxic brain edema formation following brain injury | Q44980976 | ||
| Role of arginine vasopressin V1 and V2 receptors for brain damage after transient focal cerebral ischemia. | Q45296344 | ||
| Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study | Q46313153 | ||
| Etiology, diagnostics and therapy of hyponatremias | Q46490513 | ||
| V1 receptor activation induced by hemorrhage and sympathoinhibition in the mesentery and hindquarters of spontaneously hypertensive rats. | Q46883356 | ||
| A bolus of conivaptan lowers intracranial pressure in a patient with hyponatremia after traumatic brain injury | Q48213651 | ||
| Treatment of brain edema with a nonpeptide arginine vasopressin V1 receptor antagonist OPC-21268 in rats | Q48302755 | ||
| Vasopressin V(1a) receptors mediate posthemorrhagic systemic hypertension thereby determining rebleeding rate and outcome after experimental subarachnoid hemorrhage | Q48841321 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | blood–brain barrier | Q221694 |
| AVP | Q12009087 | ||
| P304 | page(s) | e0136121 | |
| P577 | publication date | 2015-08-14 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Arginine-Vasopressin Receptor Blocker Conivaptan Reduces Brain Edema and Blood-Brain Barrier Disruption after Experimental Stroke in Mice | |
| P478 | volume | 10 |
| Q26741093 | Arginine Vasopressin and Copeptin in Perinatology |
| Q55399277 | Astroglial Modulation of Hydromineral Balance and Cerebral Edema. |
| Q92711840 | Blockade of Arginine Vasopressin receptors prevents blood-brain barrier breakdown in Experimental Autoimmune Encephalomyelitis |
| Q39446196 | Cardiorenal Syndrome: Role of Arginine Vasopressin and Vaptans in Heart Failure |
| Q49049427 | Conivaptan, a Selective Arginine Vasopressin V1a and V2 Receptor Antagonist Attenuates Global Cerebral Edema Following Experimental Cardiac Arrest via Perivascular Pool of Aquaporin-4. |
| Q38816548 | Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema. |
| Q92500707 | Emerging Pharmacological Treatments for Cerebral Edema: Evidence from Clinical Studies |
| Q39044188 | Mechanisms of Global Cerebral Edema Formation in Aneurysmal Subarachnoid Hemorrhage |
| Q38874039 | Recent advances and future directions in preclinical research of arginine-vasopressin (AVP) receptor blocker conivaptan in the context of stroke |
| Q51612114 | Telmisartan reduced cerebral edema by inhibiting NLRP3 inflammasome in mice with cold brain injury. |
| Q38602148 | Therapeutic time window for conivaptan treatment against stroke-evoked brain edema and blood-brain barrier disruption in mice |
| Q48752367 | Treatment with Isorhamnetin Protects the Brain Against Ischemic Injury in Mice |
| Q40539016 | Vasopressin Impairment During Sepsis Is Associated with Hypothalamic Intrinsic Apoptotic Pathway and Microglial Activation |
Search more.